CClinicalTrials.gg
RecruitingNCT06042348P2SSUpdated Sep 18, 2023

Placenta Perfusion and Sufficiency Study

An observational study in Placenta Diseases, Diagnosis, Pregnancy Related and Female, sponsored by Maxima Medical Center. Recruiting at 1 site in Netherlands. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-18.

Sponsored by Maxima Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Ultrasonography will be used to determine the total blood flow to and from the uterus. This is done by measuring the blood vessels coming from and going to the uterus. This wil hopefully prove viable and open the possibility to further research in the clinical relevance of these measurements.

Read the detailed description

This prospective pilot study takes place between 14- and 16-weeks' gestation (GA14 to 16 weeks). This is a feasibility study, as the perfusion measurements have not yet been performed this early in pregnancy. First the feasibility is assessed, before conducting a full-scale research project. The study will take place in a tertiary care obstetric centre, Máxima Medical Center, in Veldhoven The Netherlands. Measurements will be done at the out patient clinic of obstetrics. Duration of the study is 2 months. This gives ample time for recruitment of the subjects.

Recruitment will take place at the outpatient clinic of Máxima Medisch Centrum in Veldhoven. Women with singleton pregnancies coming for their 11-12 weeks' gestational ultrasound, where the pregnancy is dated, will be given a patient information folder in either Dutch or English and asked if the researcher can contact them. Participation is completely on voluntary basis. Patients will be called in the next days by the researcher to answer additional questions and to ask if patients are willing to participate. Contact information of the researchers will be available on the folder in case of questions.

Upon inclusion, the patients will be scheduled for a visit to perform all relevant measurements, henceforth referred to as 'measurement day' (MD) which is to take place between 14- and 16-weeks' gestation. The patient, henceforth to be referred to as participant, will be asked to rest for 5 minutes in a supine position. After 5 minutes of rest the blood pressure of the right arm will be measured, three times using the auto-sphygmomanometer. The three measurements will then be used to calculate the average systolic and diastolic blood pressures. After measurement of blood pressure, the ultrasound scan will be performed. The uterine and placental vessels will be measured according to the standard operating procedure attached to this document. All vessels will be measured 3 times during the ultrasound scan.

02

Conditions studied

  • Placenta Diseases, Diagnosis
  • Pregnancy Related
  • Female
  • Human

Browse trials for

Keywords

  • Placenta
  • Human
  • Pregnancy
  • Early pregnancy
  • Hypertension disorders
  • Uterus
  • Uterine artery
  • Uterine vein
  • Placental circulation
  • Placenta physiology
  • Netherlands
  • Placenta development
03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The base population are women with singleton pregnancies between 14- and 16 weeks' gestation.

Inclusion criteria

  • Age ≥ 18 years
  • Between 14-16 weeks gestation on measurement day
  • Placenta anterior
  • BMI \< 30kg/m2
  • Ability to give consent
  • Adequate mastery of the Dutch or English languages

Exclusion criteria

Exclusion Criteria:

  • Non-intact pregnancy at 13 week's gestational echo.
  • Vanishing twin
  • Multiple gestations
  • Congenital or anatomical anomalies at 13 weeks' gestational echo.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Group 1

    Diagnostic Test: Trans abdominal ultrasound

Interventions

  • Diagnostic testTrans abdominal ultrasound

    Ultra sound of the uterus and uterine blood vessels

05

What researchers measure

Primary outcomes

  1. Uterine blood vessel flow

    The feasibility of measuring placenta perfusion between 14-16 weeks of gestation

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. uterine vessel differences

    To assess whether there are differences in measurements between the two umbilical arteries

    Time frame: Through study completion, an average of 1 year

  2. Relation between uterine vessels

    To determine whether a relation between the uterine artery and vein flow exists

    Time frame: Through study completion, an average of 1 year

06

Study locations

1 of 1 sites recruiting
  • Maxima Medical Center
    Veldhoven, Braband, Netherlands
    Recruiting
07

References and documents

Publications

  • Gude NM, Roberts CT, Kalionis B, King RG. Growth and function of the normal human placenta. Thromb Res. 2004;114(5-6):397-407. doi: 10.1016/j.thromres.2004.06.038. PubMed 15507270 ↗
  • Fadl S, Moshiri M, Fligner CL, Katz DS, Dighe M. Placental Imaging: Normal Appearance with Review of Pathologic Findings. Radiographics. 2017 May-Jun;37(3):979-998. doi: 10.1148/rg.2017160155. PubMed 28493802 ↗
  • Brosens I, Pijnenborg R, Vercruysse L, Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011 Mar;204(3):193-201. doi: 10.1016/j.ajog.2010.08.009. Epub 2010 Nov 20. PubMed 21094932 ↗
  • Schiffer V, van Haren A, De Cubber L, Bons J, Coumans A, van Kuijk SM, Spaanderman M, Al-Nasiry S. Ultrasound evaluation of the placenta in healthy and placental syndrome pregnancies: A systematic review. Eur J Obstet Gynecol Reprod Biol. 2021 Jul;262:45-56. doi: 10.1016/j.ejogrb.2021.04.042. Epub 2021 May 4. PubMed 33984727 ↗
  • Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet. 2016 Mar 5;387(10022):999-1011. doi: 10.1016/S0140-6736(15)00070-7. Epub 2015 Sep 2. PubMed 26342729 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT06042348
Lead sponsor
Maxima Medical Center
Responsible party
Sahil Joseph Gregory Manoj Sabnani (Principal Investigator, Maxima Medical Center) — Principal investigator
First posted
Sep 18, 2023
Start date
Sep 15, 2023 (estimated)
Primary completion
Dec 1, 2023 (estimated)
Completion
Jan 31, 2024 (estimated)
Last update
Sep 18, 2023

Study contacts

Loes Monen
principal investigator · Maxima Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion